EMA
The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.
Business & Industry
- Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
- Nearly 700,000 US hospitalizations and 110,000 deaths prevented from the Pfizer-BioNTech COVID-19 vaccine
- Pfizer and BioNTech provide update on COVID-19 vaccine supply agreement with European Commission
- Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028
- Pfizer to acquire Biohaven Pharmaceuticals
Research & Development
- "Natural immunity" from omicron is weak and limited, study finds
- mRNA booster vaccines may be a good investment in developing countries
- Blocking spike captors to counter COVID
- Recurring brain tumor growth is halted with new drug
- Investigational COVID mucosal vaccine protects against disease and transmission
- Using AI to analyze large amounts of biological data
- Cognitive impairment from severe COVID-19 equivalent to 20 years of ageing, study finds
Conferences & Events
- Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
- SMi's 22nd Annual Pain Therapeutics Conference
- SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
- SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
- SMi's 3rd Annual AI in Drug Discovery Conference
- SMi's 6th Annual Highly Potent Active Pharmaceutical Ingredients
- SMi's 9th Annual Conference Pre-Filled Syringes East Coast
Regulatory Affairs
- FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
- FDA limits use of Janssen COVID-19 vaccine to certain individuals
- EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
- FDA approves first generic of Symbicort to treat asthma and COPD
- FDA approves treatment for wider range of patients with heart failure